Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2018

View Archived Issues

Blocking complement protects synapses in AD

Critical protein for intracellular antigen recognition is found

AWOL cGAS is novel DNA repair player

Alize Pharma 3 describes its first two assets

Rafael opens phase III study of CPI-613 + mFolfirinox in metastatic adenocarcinoma of the pancreas

Fas-immunomodulatory fusion protein potentiates efficacy of T-cell therapy in ovarian tumor model

Tesaro presents phase I data from AMBER study of TSR-022 plus TSR-042

AO-176, a novel anti-CD47 monoclonal antibody with a unique killing profile

Microbiota mediate metformin clinical benefits

Selective beta3-adrenoceptor antagonist APD-418 beneficial in heart failure models

Nanjing TransThera Biosciences divulges IDO-1 inhibitors

New compounds for helminthic infections discovered at Bayer Animal Health

Novartis patents HBsAG secretion inhibitors

Adynxx and twoXAR aim to discover new treatments for endometriosis

OncoTartis divulges compounds for leukemias with MLL gene translocations

Boehringer and Epizyme collaborate to develop novel epigenetic oncology therapies

Cocrystal Pharma generates new influenza polymerase basic protein 2 inhibitors

Amgen initiates first-in-human study of AMG-562

Indoleamine 2,3-dioxygenase 1 inhibitors patented by Alberta Research Chemicals

Baicalein regulates proliferation and chemosensitivity in HCC by upregulating miR-181a-5p

Isofol initiates pivotal phase III study of arfolitixorin in metastatic colorectal cancer

BO-264 is a potent and selective TACC3 inhibitor for the treatment of breast cancer

Phase III trial of fruquintinib in third-line NSCLC does not meet primary endpoint of OS

New AR degrader ARD-61 demonstrates efficacy in models of castration-resistant prostate cancer

AstraZeneca reports final OS results from MYSTIC trial of Imfinzi in stage IV NSCLC

uniQure reports initial phase IIb data on AMT-061 for hemophilia B

Biohaven initiates phase III trial of rimegepant for preventive treatment of migraine

Apolipoprotein D as a potential new target in Niemann-Pick type A disease

PsiOxus and Parker Institute collaborate on virus-based gene therapy to treat solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.